BreatheVision

Company Overview

Snapshot

Founded in October 2013 by Ditza Auerbach, BreatheVision operated with 1–10 employees. The company secured funding across two rounds, with its latest funding event occurring in June 2020.

Business overview

BreatheVision was an Israeli biotechnology startup that developed SafeSed, a device for remote breathing monitoring. SafeSed was designed to accurately measure respiratory volume and patterns, providing a cost-effective and portable solution compared to existing devices. The technology utilized a comprehensive set of variables to deliver early alerts for adverse events, aiming to prevent respiratory depression and compromise. The company operated within the Health Tech & Life Sciences sector, specifically focusing on medical devices, digital healthcare, and patient remote monitoring, serving the global market.

Strategic signal

In May 2020, BreatheVision's technology was highlighted in an article discussing its potential to save lives by tracking breath rates, particularly in the context of the coronavirus pandemic. This indicates a strategic validation of the company's remote respiratory monitoring solution and its relevance in addressing critical healthcare needs, suggesting a potential for broader adoption in emergency and critical care settings.

Company Intelligence Q&A

What is BreatheVision's primary product?

BreatheVision developed SafeSed, a device designed for remote breathing monitoring that accurately measures respiratory volume and patterns.

When was BreatheVision founded?

BreatheVision was founded in October 2013.

Who is a founder of BreatheVision?

Ditza Auerbach is a founder and CTO of BreatheVision.

What was the strategic focus of BreatheVision's technology?

BreatheVision's SafeSed device was designed to provide early alerts for adverse events, aiming to prevent respiratory depression and respiratory compromise through comprehensive variable monitoring.